Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18321 |
Mc-Val-Cit-PAB-Cl
|
Others | Others |
Mc-Val-Cit-PAB-Cl 是一种可切割的 ADC 接头,可用于偶联 MMAE 和抗体以形成抗体-MC-vc-MMAE。 | |||
T5149 |
MC-Val-Cit-PAB
N-[6-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)-1-氧代己基]-L-缬氨酰-N5-(氨基甲酰基)-N-[4-(羟甲基)苯基]-L-鸟氨酰胺 |
Others; AChR | Neuroscience; Others |
MC-Val-Cit-PAB 是一种组织蛋白酶可裂解的 ADC 接头,用于制备抗体-药物偶联物。 | |||
T77847 |
MC-Val-Cit-PAB-Exatecan
MC-Val-Cit-PAB-DX8951 |
||
MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) 是一种抗体-活性分子偶联物(ADC)的关键部分,由 DNA 拓扑异构酶 I 抑制剂 DX-8951 和组织蛋白酶敏感的连接子共同构成。 | |||
T18330 |
MC-Val-Cit-PAB-vinblastine
|
Others | Others |
MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB ADC linker. | |||
T18327 |
MC-Val-Cit-PAB-Retapamulin
|
Others | Others |
MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for antibody-drug conjugates (ADC) that exhibits potent antitumor activity. This compound utilizes Retapamulin, a ribosome inhibitor, connected through the ADC linker MC-Val-Cit-PAB. | |||
T18323 |
MC-Val-Cit-PAB-dimethylDNA31
|
Others | Others |
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to link to the potent antitumor agent dimethylDNA31. Notably, dimethylDNA31 also demonstrates significant bactericidal activity against both persister and stationary-phase Staphylococcus aureus. | |||
T18328 |
MC-Val-Cit-PAB-rifabutin
|
Others | Others |
MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate designed for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected through the MC-Val-Cit-PAB ADC linker. This configuration endows it with significant antitumor activity. | |||
T18320 |
MC-Val-Cit-PAB-carfilzomib iodide
MC-Val-Cit-PAB-carfilzomib |
Others | Others |
MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB. | |||
T18324 |
MC-Val-Cit-PAB-duocarmycin chloride
MC-Val-Cit-PAB-duocarmycin |
Others | Others |
MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity. | |||
T33243 |
MC-Val-Cit-PAB-VX765
Belnacasan-conjugate,VX765-conjugate,MC-Val-Cit-PABC-VX765 |
||
MC-VAL-CIT-PAB-VX765 or MC-VAL-CIT-PABC-VX765 is a VX765 derivative that can be conjugated to antibodies, proteins, or polymers for targeted drug delivery. MC-Val- CIT -PAB is a cathepsin cleavable ADC connector, which has been widely used in the preparat | |||
T18326 |
MC-Val-Cit-PAB-MMAF
|
Others | Others |
MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB. | |||
T18325 |
MC-Val-Cit-PAB-Indibulin
|
Others | Others |
MC-Val-Cit-PAB-Indibulin is an antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), featuring the orally active tubulin assembly inhibitor, Indibulin, connected through the MC-Val-Cit-PAB ADC linker. This compound exhibits potent antitumor activity. | |||
T18322 |
MC-Val-Cit-PAB-clindamycin
|
Others | Others |
MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker that combines the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, to enhance its ability to target and kill cancer cells effectively. | |||
T18319 |
MC-Val-Cit-PAB-Auristatin E
|
Others | Others |
MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound featuring Auristatin E, a potent cytotoxic tubulin modifier, connected through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity. | |||
T31567 |
Doxorubicin-MVCP
MC-Val-Cit-PAB-Doxorubicin,MC-Val-Cit-PAB-Dox |
||
Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker. | |||
T18329 |
MC-VC(S)-PABQ-Tubulysin M
MC-Val-Cit-PAB-tubulysin5a |
Others | Others |
MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB. | |||
T77875 |
Mc-Val-Cit-PAB-Gefitinib chloride
|
||
Mc-Val-Cit-PAB-Gefitinibchloride是一种担载EGFR酪氨酸激酶抑制剂Gefitinib的ADC活性分子连接子偶联物,由Gefitinib和专为ADC设计的连接子Mc-Val-Cit-PAB构成。 | |||
T77826 |
MC-Val-Cit-PAB-NH-C2-NH-Boc
|
||
MC-Val-Cit-PAB-NH-C2-NH-Boc 为一种ADC连接子,能被cathepsin降解,适用于抗体药物偶联体(ADC)的合成。 | |||
T74468 |
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
|
||
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) 是一种 HER2-TLR7和 HER2-TLR8免疫激动剂复合物。 | |||
T33861 | Paclitaxel-MVCP | ||
Paclitaxel-MVCP ( MC-val-cit-pab-paclitaxel )is a paclitaxel derivative with an MC-Val-Cit-PAB linker, which can be used for the preparation of Paclitaxel conjugates for drug delivery and nanomedicine research. | |||
T77839 |
Bi-Mc-VC-PAB-MMAE
|
||
Bi-Mc-VC-PAB-MMAE是由ADC linker (Fmoc-Val-Cit-PAB) 与MMAE构成,后者为一种有效的(tubulin)抑制剂,用于偶联抗体。 |